We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
26
Puma Biotechnology
PBYI
$454M
$28.1M 1.08%
475,800
+62,900
+15% +$3.65M
TSRO
27
DELISTED
TESARO, Inc.
TSRO
$27.8M 1.07%
625,400
+52,400
+9% +$2.55M
AXGN icon
28
Axogen
AXGN
$2.5B
$27.4M 1.05%
545,000
+40,000
+8% +$1.76M
PRAH
29
DELISTED
PRA Health Sciences, Inc.
PRAH
$26.9M 1.04%
288,247
-106,753
-27% -$9.19M
WMGI
30
DELISTED
Wright Medical Group Inc
WMGI
$26M 1%
1,000,000
– –
GILD icon
31
Gilead Sciences
GILD
$165B
$25.9M 1%
365,000
+51,600
+16% +$3.64M
MDCO
32
DELISTED
Medicines Co
MDCO
$25.3M 0.97%
690,000
– –
TFX icon
33
Teleflex
TFX
$5.98B
$24.8M 0.95%
92,500
– –
ALDR
34
DELISTED
Alder Biopharmaceuticals
ALDR
$24.7M 0.95%
1,565,000
+35,200
+2% +$535K
EW icon
35
Edwards Lifesciences
EW
$51.7B
$24M 0.92%
495,000
-75,003
-13% -$3.5M
EXAS
36
DELISTED
Exact Sciences
EXAS
$22.7M 0.87%
380,000
+9,500
+3% +$511K
ALGN icon
37
Align Technology
ALGN
$12.3B
$22.6M 0.87%
66,000
+500
+0.8% +$149K
INGN icon
38
Inogen
INGN
$164M
$22.2M 0.85%
119,000
+8,500
+8% +$1.41M
BAX icon
39
Baxter International
BAX
$14.2B
$21.9M 0.84%
297,000
– –
HRTX icon
40
Heron Therapeutics
HRTX
$92.9M
$20.4M 0.78%
525,000
+49,000
+10% +$1.56M
TMO icon
41
Thermo Fisher Scientific
TMO
$220B
$19.9M 0.77%
96,000
-18,500
-16% -$3.93M
INCY icon
42
Incyte
INCY
$24.4B
$19.8M 0.76%
296,000
+113,500
+62% +$7.76M
INSM icon
43
Insmed
INSM
$28.6B
$19.5M 0.75%
825,000
– –
NUVA
44
DELISTED
NuVasive, Inc.
NUVA
$19.4M 0.75%
372,500
+67,500
+22% +$3.54M
KYNB
45
Kyntra Bio
KYNB
$29.4M
$19.2M 0.74%
12,280
-100
-0.8% -$130K
COR icon
46
Cencora
COR
$61.2B
$18.8M 0.72%
220,000
-75,000
-25% -$6.59M
ZBH icon
47
Zimmer Biomet
ZBH
$18.4B
$17.9M 0.69%
165,830
+13,905
+9% +$1.51M
MRSN
48
DELISTED
Mersana Therapeutics
MRSN
$17.9M 0.69%
40,000
-12,000
-23% -$5.27M
ASMB icon
49
Assembly Biosciences
ASMB
$529M
$17.6M 0.68%
37,500
+583
+2% +$308K
ACRS icon
50
Aclaris Therapeutics
ACRS
$869M
$17.1M 0.66%
856,000
+326,000
+62% +$6.02M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.